A phase 3, RATIONALE-306 study that was global, randomized, double-blind, parallel-arm, and placebo-controlled was carried out at 162 medical centers in Asia, Europe, Oceania, and North America. The present study provides interim analysis outcomes from the RATIONALE-306 trial, which aimed to evaluate the efficacy of tislelizumab. Tislelizumab, an anti-PD-1 antibody, has demonstrated antineoplastic […]...
SGO 2023
Coverage of Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 2023
Mar 25
-Mar 28, 2023